MONTREAL, Nov. 26, 2014 /CNW Telbec/ - DMD Digital Health Connections Group Inc. formerly known as Aptilon Corporation (the "Company" or "DMD") (NEX: DMG.H), reported a net income of $0.9 million for the nine-month period ended September 30, 2014 on revenues of $14.9 million compared to a net loss of $1.9 million on revenues of $12.5 million for the nine-month period ended September 30, 2013, an improvement of $2.4 million.
The Company reported an operating income before net finance expense of $2.4 million for the nine-month period ended September 30, 2014 compared to an operating income before net finance expense of $1.1 million for the nine-month period ended September 30, 2013.
Over the past two years, the Company has introduced new products and services and brought changes to its sales team that enabled the Company to successfully increase its sales and expanded its client base. The first nine months of the year reflect the success of these changes as well as continued growth in large pharmaceutical accounts. In the latest quarter, the Company launched its Superfile (SM) which comprehensively covers the demographic, affiliation and practice data for 1 million physicians and 5 million mid-level health practitioners. The Company also renegotiated a portion of its long-term debt in the last quarter of 2013 which had a positive impact on net income through the reduction of net finance expense of $1.4 million for the nine-month period ended September 30, 2014.
For the three months ended September 30, 2014, the Company reported a net income of $0.1 million on revenues of $4.7 million compared to a net loss of $0.3 million on revenues of $4.3 million for the three months ended September 30, 2013.
The Company reported an operating income before net finance expense of $0.6 million for the quarter ended September 30, 2014 compared with an operating income before net finance expense of $0.7 million for the quarter ended September 30, 2013.
During the quarter, the Company continued to improve and expand its data services product offering to consolidate its position as the email communication channel of choice for healthcare companies to reach professionals through web and mobile technology.
Complete financial statements and MD&A for the nine-month and three-month periods ended September 30, 2014 are available on SEDAR at www.sedar.com.
About DMD Digital Health Connections Group Inc. ("DMD")
DMD enables pharmaceutical, pharmaceutical marketing companies, digital advertising agencies and medical device companies to effectively reach, message, connect and interact with US physicians and healthcare professionals via multiple access channels. Its innovative service offerings provide targeted impressions and interactions through permission-based email, targeted on-line ad-serving, and mobile app advertising channels. Top pharmaceutical companies, agencies and respected healthcare organizations have adopted DMD's solutions to target, engage and interact with leading healthcare practitioners. For more information, visit www.dmdconnects.com.
This news release contains forward-looking information. These statements relate to future events or future performance and reflect management's current expectations and assumptions. Such forward-looking statements reflect management's current beliefs and are based on information currently available to management of DMD. A number of factors could cause actual events, performance or results to differ materially from the events performance and results discussed in the forward-looking statements. These forward-looking statements are made as of the date hereof and DMD does not assume any obligation to update or revise them to reflect new events or circumstances.
Neither NEX, the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE: DMD Digital Health Connections Group Inc.
For further information: André Charron, CFO, DMD Digital Health Connections Group Inc., 514-769-5858, [email protected]